Online inquiry

IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9998MR)

This product GTTS-WQ9998MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FGF23 gene. The antibody can be applied in Dermatological genetic disorders research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_020638.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8074
UniProt ID Q9GZV9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9998MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1382MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ6451MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CT-P23
GTTS-WQ6597MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ11902MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ3644MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ1252MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ8182MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ6450MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-P23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW